https://www.marketscreener.com/quote/stock/NXERA-PHARMA-CO-LTD-6814799/news/Sosei-Group-Corporation-Doses-First-Subject-in-a-Phase-1-Trial-Evaluating-its-Novel-EP4-Receptor-Ago-46248012/?utm_source=telegram&utm_medium=social&utm_campaign=share